Clinical trials: Infectious Encephalitis
Japanese Encephalitis
Post-licensure Safety Study of IMOJEV® in Thailand
The aim of this study is to further characterize the safety profile of IMOJEV®. Primary Objective: To describe serious adverse events (SAEs, including adverse events of special interest [AESIs]) up to 60 days after administration…
- Trial name
- NCT01981967
- Testing
- IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine
- Where
- 8 sites in Thailand
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Encephalitis, Tick-Borne
Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
The objective of this study is to assess the immunogenicity, safety and interchangeability of two different TBE vaccines in children aged 1-11 years, the first and second vaccination with either FSME-IMMUN 0.25ml Junior or…
- Trial name
- NCT00840801
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 8 sites in Austria, Czechia
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Pfizer
Japanese Encephalitis
Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine
The purpose of this study is to assess the safety, tolerability, and immunogenicity of a new formulation of lyophilised ChimeriVax™-JE, given at three dose levels, compared with placebo.
- Trial name
- NCT00981630
- Testing
- Live attenuated Japanese encephalitis virus
- Where
- 2 sites in Australia
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Sanofi
Encephalitis, Myelitis
Neurologic Manifestations of the Arbovirus Infection in Colombia
This is a multi-center case-control study that aims to define the association between the exposure to an arbovirus infection and the development of a neurological syndrome in patients from Colombia.
- Conditions
- Encephalitis, Myelitis, Guillain-Barre Syndrome, Cranial Nerve Palsies
- Trial name
- NCT03206541
- Where
- 8 sites in Colombia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Japanese Encephalitis
Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age
To facilitate introduction of live attenuated SA 14-14-2 Japanese encephalitis vaccine (LJEV) into the National Immunization Programme of Sri Lanka, we evaluated the safety and immunogenicity of co-administration of LJEV and…
- Trial name
- JEV03 (NCT00463684)
- Testing
- Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine, Live, attenuated measles vaccine
- Where
- 3 sites in Sri Lanka
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- PATH
Encephalitis
A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants
Japanese encephalitis (JE) is an acute viral zoonotic disease. Neurologic manifestations of the disease range from subtle changes in behavior to serious problems, including blindness, ataxia, weakness, and movement disorders.
- Trial name
- NCT02367664
- Testing
- 0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine, 0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine, 0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell)
- Where
- China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Malaria, Dengue
Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR
Rural communities involved in agriculture are often at highest risk of insect-borne diseases in Southeast (SE) Asia. Skin-applied insect repellents may prove a useful means of reducing mosquito-borne diseases for those people…
- Conditions
- Malaria, Dengue, Japanese Encephalitis
- Trial name
- NCT00938379
- Testing
- 20% deet insect repellent
- Where
- Laos
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Encephalitis, Japanese B
Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine
The previously conducted JEV01 study looked at the immunogenicity and safety of the concurrent administration of Japanese Live Attenuated SA 14-14-2 and measles vaccines at the one month post vaccination time point.
- Trial name
- NCT00412516
- Testing
- Live attenuated SA 14-14-2 vaccine
- Where
- Philippines
- Volunteers
- 519 people, healthy volunteers welcome
- Sponsor
- PATH
Japanese Encephalitis
Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea
To assess the immunogenicity and safety of the vero cell-derived inactivated JE vaccine in Korean healthy children aged 12~23 months
- Trial name
- NCT01150942
- Testing
- JE vaccine
- Where
- South Korea
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Venezuelan Equine Encephalitis Virus Infection
Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers
The Phase I study will assess the basic safety, tolerability, and immunogenicity of a DNA-based Venezuelan equine encephalitis virus (VEEV)vaccine candidate delivered by electroporation .
- Trial name
- NCT01984983
- Testing
- Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Ichor Medical Systems Incorporated
Japanese Encephalitis
Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
The study investigates the long term persistence the Japanese encephalitis vaccine IC51 and the need of a booster dose
- Trial name
- NCT00595270
- Testing
- IC51
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51
The study investigates the long term safety and immunogenicity of the Japanese Encephalitis vaccine IC51 up to month 60.
- Trial name
- NCT00596102
- Testing
- Japanese Encephalitis purified inactivated vaccine
- Volunteers
- 3,258 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Yellow Fever, Encephalitis, Japanese
The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans
Epidemic viral diseases have become more prevalent in recent years. Among the various strategies to prevent such epidemics, vaccination is the most cost-effective.
- Trial name
- NCT01943305
- Testing
- Japanese Encephalitis vaccine, Yellow Fever vaccine
- Where
- Singapore
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Japanese Encephalitis
Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea
The aim of this study was to document the immunogenicity and safety of a booster dose of IMOJEV administered at least 12 months after the primary dose.
- Trial name
- NCT01900444
- Testing
- IMOJEV
- Where
- 8 sites in South Korea
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Encephalitis, Japanese Encephalitis
Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.
The purpose of this study is to assess whether ChimeriVax™ JE vaccine (a new vaccine to be used for vaccination against Japanese encephalitis) is safe and well tolerated when compared to placebo (dummy) vaccination.
- Trial name
- NCT00314132
- Testing
- ChimeriVax-JE, Japanese Encephalitis vaccine, 0.9% Saline
- Where
- 22 sites in United States, Australia
- Volunteers
- 2,004 people, healthy volunteers welcome
- Sponsor
- Sanofi
Japanese Encephalitis
Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects
The purpose of this study is to describe the immunogenicity and safety of IMOJEV® in adult and pediatric populations in Vietnam and serve a bridging study to compare immunogenicity, reactogenicity, and safety data obtained with…
- Trial name
- NCT02492165
- Testing
- Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
- Where
- Vietnam
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Tick-borne Encephalitis
New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
The risk for tick borne encephalitis increases in Sweden. Together with an increased awareness of the possibility to acquire protection by vaccination, this has led to an increase in the number of doses of the vaccine distributed…
- Trial name
- NCT02318069
- Testing
- FSME-immune
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sormland County Council, Sweden
Eastern Equine Encephalitis
Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine
This study is designed to determine the safety and immunogenicity of Eastern Equine Encephalitis (EEE) Vaccine.
- Trial name
- EEE (NCT00584805)
- Testing
- Inactivated, Dried, TSI-GSD 104, EEE
- Where
- United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Encephalitis, Japanese B
Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine
This study will determine whether it is safe and effective to administer Japanese encephalitis (JE) live attenuated SA 14-14-2 vaccine at the same time as measles vaccine.
- Trial name
- NCT00249769
- Testing
- Live Japanese encephalitis vaccine SA 14-14-2 (LJEV), Measles Vaccine (MV)
- Where
- Philippines
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PATH
Encephalitis, Tick-borne
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
The objective of this study is to establish the earliest time point at which vaccines are expected to show seropositive antibody levels after vaccination with FSME-IMMUN 0.5 mL using a rapid immunization schedule (2 vaccinations…
- Trial name
- NCT00161954
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer